ORMP — Oramed Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $171.80m
- $121.19m
- $2.00m
Annual cashflow statement for Oramed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 4 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-Q | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.3 | -37.8 | 5.09 | -19.1 | 64 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.81 | 10.7 | -12.9 | 7.3 | -79.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.699 | -0.943 | -2.7 | 3.2 | -1.91 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -11.1 | -27.9 | -10.3 | -8.41 | -9.14 |
| Capital Expenditures | -0.009 | -0.496 | -0.254 | -0.018 | -0.009 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -99.2 | 30.7 | -72.8 | 106 | 5.45 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -99.2 | 30.2 | -73 | 106 | 5.44 |
| Financing Cash Flow Items | — | -0.783 | — | -0.002 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 60.6 | 10.8 | 52 | -52 | -4.74 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -49.8 | 13 | -31.4 | 45.4 | -8.47 |